Deep Track Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Deep Track Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36.5M	Buy	+2,491,539	New	+$39.8M	0.6%	39

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deep Track Capital's CRVS Position: Q1 2026 in Review

Deep Track Capital opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 2,491,539 shares worth $36.5M. The stake represents 0.6% of the portfolio and ranks #39 among its holdings.

164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Deep Track Capital held 2,491,539 shares of Corvus Pharmaceuticals worth $36.5M as of Q1 2026.
Corvus Pharmaceuticals was a new Deep Track Capital position in Q1 2026.
Corvus Pharmaceuticals made up 0.6% of Deep Track Capital's portfolio in Q1 2026, its #39 holding.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.